Research in social & administrative pharmacy : RSAP · 2025
Impact of medication therapy management on medication adherence and health-related quality of life among non-dialysis chronic kidney disease patients.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sirimalla Shivaprasad, Mateti Uday Venkat, Shenoy Pradeep, Shastry C S, Shetty Shraddha
Аннотация
BACKGROUND: Chronic kidney disease (CKD) is a progressive disease, often associated with poor medication adherence and reduced health related quality of life (HRQoL). Medication therapy management (MTM) is a range of services provided to patients and has been shown to enhance medication adherence and HRQoL, yet its impact on non-dialysis CKD patients remains underexplored. So, the study was aimed to see the impact of MTM on medication adherence and HRQoL among non-dialysis CKD patients.
METHODOLOGY: The prospective, open-labelled randomization-controlled study was conducted among CKD non-dialysis patients. HRQoL was assessed using KDQoL-36 questionnaire. Medication adherence was assessed using the medication adherence scale. Both were assessed at baseline; 6th and 12th month follow up. MTM group received clinical pharmacist's MTM services along with usual care (UC). UC group received the hospital team's general care from the Doctors, Nurses, and other health care professionals.
RESULTS: A total of 220 CKD patients has been enrolled into the both groups in 1:1 ratio. At baseline, most of the patients were having medium adherence in both MTM 82 (74.54) and UC 77 (70) groups, followed by low adherence with p value 0.131. At 6th and 12th month follow-up. Medication adherence was increased in the MTM group compared to the UC group with p value <0.001. In the baseline, the more HRQoL score was found in the domain "symptoms and problems list" in both MTM 70.4 and UC groups 71.5 with the p value >0.05. The HRQoL scores of 5 domains were significantly increased at the 6th month and 12th month in the MTM group compared to the UC group with p value <0.05.
CONCLUSION: Study concluded, MTM services increased the medication adherence and HR-QoL of CKD non dialysis patients in MTM group compared to UC group. In future, MTM services can be implemented in healthcare settings.
METHODOLOGY: The prospective, open-labelled randomization-controlled study was conducted among CKD non-dialysis patients. HRQoL was assessed using KDQoL-36 questionnaire. Medication adherence was assessed using the medication adherence scale. Both were assessed at baseline; 6th and 12th month follow up. MTM group received clinical pharmacist's MTM services along with usual care (UC). UC group received the hospital team's general care from the Doctors, Nurses, and other health care professionals.
RESULTS: A total of 220 CKD patients has been enrolled into the both groups in 1:1 ratio. At baseline, most of the patients were having medium adherence in both MTM 82 (74.54) and UC 77 (70) groups, followed by low adherence with p value 0.131. At 6th and 12th month follow-up. Medication adherence was increased in the MTM group compared to the UC group with p value <0.001. In the baseline, the more HRQoL score was found in the domain "symptoms and problems list" in both MTM 70.4 and UC groups 71.5 with the p value >0.05. The HRQoL scores of 5 domains were significantly increased at the 6th month and 12th month in the MTM group compared to the UC group with p value <0.05.
CONCLUSION: Study concluded, MTM services increased the medication adherence and HR-QoL of CKD non dialysis patients in MTM group compared to UC group. In future, MTM services can be implemented in healthcare settings.